Navigation Links
GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
Date:10/20/2008

ATLANTA, Oct. 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today it has shipped both DNA and MVA components of its AIDS vaccine to the HIV Vaccine Trials Network (HVTN) pharmacy, for use in the upcoming Phase 2a human clinical trial. This Phase 2a study will involve 150 vaccinees and 75 placebo (control) participants. These trials serve as a major milestone, as Phase 2a trials are the most advanced trials to-date for GeoVax.

Dr. Robert McNally, President and CEO of GeoVax Labs Inc., commented, "The shipment of the vaccine to the HIV Vaccine Trials Network is a significant step in preparation for the largest clinical trial yet to be undertaken by GeoVax. Multiple completed Phase 1 safety trials refined the dose and vaccine delivery intervals to optimize the immune responses considered desirable to achieve protection against the HIV-1 virus causing AIDS."

Further, a Biological Master File has been submitted to the Food and Drug Administration (FDA) for review of the manufacturing data for the product shipped to HVTN for use in the Phase 2a trial. The FDA completes its review within four weeks. Upon FDA clearance, HVTN's pharmacy will release GeoVax's DNA and MVA vaccines for its planned Phase 2a trial commencement.

GeoVax AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS) caused by the virus known as HIV-1 by vaccinating individuals prior to virus infection. The vaccine regimen employs a two component "prime-boost strategy." Trial participants are first administered GeoVax HIV-1 DNA vaccine which "primes" the immune system followed by the second vaccine, GeoVax's HIV-1 MVA (Modified Vaccinia Virus) boost. Both vaccines express the 3 major proteins of the AIDS virus. These proteins mimic more than 50% of the
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
2. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
3. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
4. Nanoemulsion vaccines show increasing promise
5. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
6. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
7. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
8. Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
9. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
10. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
11. GeoVax Presents Data at AIDS Vaccine 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 01, 2015 Shimadzu Corporation announced ... Unified Chromatography system (Nexera UC) received the Pittcon ... on Analytical Chemistry and Applied Spectroscopy (Pittcon) held ... 12th. , The Pittcon Editors’ Awards recognize ... the first time based on votes by the ...
(Date:4/1/2015)... 2015  VLP Therapeutics, LLC. ("VLP"), a ... and development of therapeutic and preventative vaccines and next ... vaccine technology, today announced that it has entered into a ... Nagasaki University in ... and development of dengue vaccine candidates. ...
(Date:4/1/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC ... to announce that Biohaven Pharmaceutical Holding Company Limited ... into an agreement with inVentiv Health for the ... their lead compound (BHV-0223). Biohaven ... clinical stage neuroscience compounds targeting the glutamatergic system. ...
(Date:4/1/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/8dzk58/blood_screening ) ... Screening Market by Technology (Nucleic Acid Amplification Test, ... Western Blotting), Product (Instrument, Reagent) & End User ... report to their offering. The ... billion by 2019 from $1.5 billion in 2014, ...
Breaking Biology Technology:Shimadzu Nexera UC Recognized at Pittcon 2015 with Editors’ Gold Award 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 2VLP Therapeutics Enters Collaboration with Institute of Tropical Medicine, Nagasaki University 3Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 2Global Blood Screening (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting) Market 2015-2019 3
... AMSTERDAM, October 13 Amsterdam ... human gene therapy,announced today that the European Medicines Agency ... AMT-080 for the treatment of,Duchenne muscular dystrophy. , ... dystrophy (DMD) entitles,AMT to ten year market exclusivity in ...
... Chopra ... Stephanie Simonton, have created "Return to Wholeness: A Mind-body Approach to Healing Cancer" ... to strengthen their immune system, reduce the side effects of treatment, and awaken the ... ...
... BOZEN, Italy, October 12 ... installation of the first,five i.v.STATION post-prototype robots in the ... to November timeframe this year; concurrently,Health Robotics also made ... Science Park 3L 3T Innovation Award, which is given ...
Cached Biology Technology:AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 2AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 3Healing Cancer Through Mind-Body Medicine: The Chopra Center Releases Pioneering DVD for Every Stage of Treatment 2Healing Cancer Through Mind-Body Medicine: The Chopra Center Releases Pioneering DVD for Every Stage of Treatment 3Health Robotics Announces First Five i.v.STATION(TM) Robot Shipments and Receipt of 3L/3T Innovation Award 2Health Robotics Announces First Five i.v.STATION(TM) Robot Shipments and Receipt of 3L/3T Innovation Award 3
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
(Date:4/2/2015)... , April 2, 2015 ... touch fingerprint sensor FPC1025 from the distributor World Peace ... commence during Q2 2015 although the major part of ... sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of ...
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... CAMBRIDGE, MA -- Earthworms creep along the ground by ... their bodies, inching forward with each wave of contractions. ... peristalsis, to get around, and our own gastrointestinal tracts ... esophagus to push food to the stomach. Now ...
... Rochelle, NY, August 9, 2012Despite criticism from Congressional Republicans ... Rim of the Pacific (RIMPAC) 2012 international maritime exercises, ... biofuels blend. The Navy contends that renewable energy resources ... in enhancing national security and energy independence. Tom Hicks, ...
... trees are one of the biggest contributors to air ... chemicals many of which are produced by human ... air. New research from a team led by Carnegie ... formed from pine tree emissions are much more chemically ...
Cached Biology News:Soft autonomous robot inches along like an earthworm 2Soft autonomous robot inches along like an earthworm 3US Navy defends renewable fuels strategy in Industrial Biotechnology Journal 2Carnegie Mellon study shows skin-aging radicals age naturally formed particles in the air 2Carnegie Mellon study shows skin-aging radicals age naturally formed particles in the air 3
... ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H 15 ... ,M.W.= 408.63 ,Assay: Greater than ... DMF) ,Biological Activity: Blue color with ... Agrees with theoretical values ,Thin Layer ...
Immunochemistry 1 & 2...
Vertical Rack (five box vapor phase rack), includes 2.0" (5.1cm) boxes...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Biology Products: